FDA Approves new drug for advanced prostate cancer

22 May 2013 4:58 PM | Lori Aubrey (Administrator)
Xofigo approved three months ahead of schedule under priority review program

Bayer HealthCare Pharmaceuticals Inc. is pleased to announce that the FDA has approved Xofigo®(radium Ra 223 dichloride) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.

FDA Approvals


Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948

This website brought to you by:

Powered by Wild Apricot Membership Software